How to report results of prothrombin and activated partial thromboplastin times

被引:20
|
作者
Tripodi, Armando [1 ,2 ]
Lippi, Giuseppe [3 ]
Plebani, Mario [4 ]
机构
[1] Univ Milan, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Dept Clin Sci & Community Hlth, I-20122 Milan, Italy
[2] IRCCS Ca Granda Maggiore Hosp Fdn, I-20122 Milan, Italy
[3] Acad Hosp Parma, Lab Clin Chem & Hematol, Parma, Italy
[4] Univ Hosp Padua, Dept Lab Med, Padua, Italy
关键词
coagulation; hemostasis; results expression; standardization; thrombosis; INTERNATIONAL NORMALIZED RATIO; DISSEMINATED INTRAVASCULAR COAGULATION; LIVER-DISEASE MELD; ANTICOAGULANT-THERAPY; SCORING SYSTEM; STANDARDIZATION; HEPARIN; CALIBRATION; HEMOSTASIS; THROMBOSIS;
D O I
10.1515/cclm-2015-0657
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Prothrombin time (PT) and activated partial thromboplastin time (APTT) are the most widely used tests to investigate coagulation abnormalities. Varied result reporting have been introduced over the years for the two tests, thus making their interpretation rather confusing in different clinical settings. PT results have been reported as clotting time, percentage activity, PT-ratio (patient-to-normal clotting time) and as international normalized ratio (INR). The INR scale has been devised to harmonize results stemming from different thromboplastins from patients on treatment with vitamin K antagonists. Therefore, there are some theoretical and evidence-based considerations that make the INR formally invalid when the test is used to analyze patients in other clinical settings. Unfortunately, this limitation has been frequently overlooked, and the INR has been (and is currently) used as a universal system of results harmonization. The APTT has been historically reported as clotting time or as ratio (patient-to-normal clotting time). In this opinion paper we review the current state-of-the-art for result reporting and attempt to give practical guidance on how PT and APTT should be reported in different clinical conditions for which the tests are requested.
引用
收藏
页码:215 / 222
页数:8
相关论文
共 50 条
  • [41] Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects
    De Kam, Pieter-Jan
    Grobara, Peter
    Prohn, Marita
    Hoppener, Floris
    Kluft, Cornelis
    Burggraaf, Jacobus
    Langdon, Ronald B.
    Peeters, Pierre
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2014, 52 (03) : 227 - 236
  • [42] Mixing Studies in Patients With Prolonged Activated Partial Thromboplastin Time or Prothrombin Time
    Benzon, Honorio T.
    Park, Meghan
    McCarthy, Robert J.
    Kendall, Mark C.
    Lindholm, Paul F.
    ANESTHESIA AND ANALGESIA, 2019, 128 (06): : 1089 - 1096
  • [43] AN ANALYSIS OF DUPLICATE TESTING OF PROTHROMBIN TIME AND ACTIVATED PARTIAL THROMBOPLASTIN TIME ASSAYS
    KRAMER, G
    BRADLOW, BA
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1991, 95 (01) : 77 - 81
  • [44] SHORTENED PROTHROMBIN (PT), ACTIVATED PARTIAL THROMBOPLASTIN TIMES (PTT) AND ANTICARDIOLIPIN ANTIBODIES (ACLS) IN PATIENTS WITH ANTIPHOSPHOLIPID (APL) ASSOCIATED DISEASES
    CONTI, AM
    GOLDBERG, SN
    GRECO, TP
    ARTHRITIS AND RHEUMATISM, 1992, 35 (09): : S109 - S109
  • [45] ACTIVATED CLOTTING TIMES AND WHOLE-BLOOD ACTIVATED PARTIAL THROMBOPLASTIN TIMES DURING CORONARY INTERVENTION
    CARTER, AJ
    BLUMENTHAL, RS
    GLOTH, ST
    DALAL, JN
    COOMBS, VJ
    RESAR, JR
    BRINKER, JA
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, : A185 - A185
  • [49] Prolongation of the prothrombin time and activated partial thromboplastin time in children with sickle cell disease
    Raffini, Leslie J.
    Niebanck, Alison E.
    Hrusovsky, Joanne
    Stevens, Amanda
    Blackwood-Chirchir, Anne
    Ohene-Frempong, Kwaku
    Kwiatkowski, Janet L.
    PEDIATRIC BLOOD & CANCER, 2006, 47 (05) : 589 - 593
  • [50] Whole blood measurement of prothrombin time and activated partial thromboplastin time in a pediatric population
    Kip, KT
    Kline, S
    Albert, M
    Smith, M
    PEDIATRIC RESEARCH, 1996, 39 (04) : 927 - 927